早期2型糖尿病中胰岛素治疗改善β细胞功能与血糖的血糖阈值:葡萄糖毒性逆转研究
该研究对108例早期2型糖尿病成人进行3周短期强化胰岛素治疗,通过口服葡萄糖耐量试验评估β细胞功能,建模分析基线空腹血糖与β细胞功能改善的关系。结果显示该关系呈非线性,空腹血糖9.3 mmol/L为拐点,超过该阈值者β细胞功能和血糖改善均被放大,符合葡萄糖毒性逆转。
要点
- 短期强化胰岛素治疗可改善早期2型糖尿病患者的β细胞功能与血糖。
- 基线空腹血糖与β细胞功能改善呈非线性关系,拐点为9.3 mmol/L。
- 基线空腹血糖超过9.3 mmol/L者,β细胞功能和血糖改善均被放大。
核心结论
- 短期强化胰岛素治疗对β细胞功能和血糖的改善在基线空腹血糖超过既定阈值者中被放大,符合葡萄糖毒性逆转。
研究设计与样本
- 对108例2型糖尿病成人(平均病程1.8±1.4年)给予3周强化胰岛素治疗(甘精胰岛素、赖脯胰岛素)。
- 治疗前后行口服葡萄糖耐量试验,以胰岛素分泌敏感性指数-2及胰岛素生成指数/稳态模型胰岛素抵抗评估β细胞功能。
- 对基线空腹血糖从6.0至10.5 mmol/L的每一水平,建模比较处于或高于该水平者与低于该水平者之间强化胰岛素治疗所致β细胞功能百分比变化的差异。
主要发现
- 基线空腹血糖与β细胞功能差异变化的关系呈非线性,最佳拟合为三次回归模型,拐点(放大)位于空腹血糖9.3 mmol/L。
- 基线空腹血糖9.3 mmol/L同时识别出空腹血糖和2小时血糖非线性降低均被放大的拐点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Alleviation of unrecognized glucotoxicity, with resultant recovery of β-cell function, could amplify the glucose-lowering effect of pharmacotherapy and contribute to the variable therapeutic response observed among patients with type 2 diabetes (T2D). However, clinical evidence supporting this concept is lacking. Short-term intensive insulin therapy (IIT) can ameliorate glucotoxicity and improve β-cell function in early T2D. Thus, for evidence of recovery of glucotoxicity-associated β-cell dysfunction, we sought to determine whether there exists a baseline fasting glucose threshold above which the post-IIT improvement in both β-cell function and glycemia is amplified. RESEARCH DESIGN AND METHODS: IIT (glargine, lispro) was administered for 3 weeks to 108 adults with T2D (mean duration 1.8 ± 1.4 years). Oral glucose tolerance tests before and after IIT enabled assessment of β-cell function by Insulin Secretion-Sensitivity Index-2 and insulinogenic index/HOMA-insulin resistance. For each level of baseline fasting glycemia from 6.0 to 10.5 mmol/L, we modeled the difference in IIT-induced percentage change in β-cell function between those at/above the indicated glucose level and those below it. RESULTS: The relationship between baseline fasting glucose and the differential change in β-cell function was nonlinear. Instead, this relationship was best fit by a cubic regression model with inflection (amplification) at fasting glucose at 9.3 mmol/L. Moreover, baseline fasting glucose at 9.3 mmol/L also identified the inflection point at which nonlinear reductions in fasting glucose and 2-h glucose, respectively, were both amplified. CONCLUSIONS: The respective improvements in β-cell function and glycemia in response to short-term IIT are amplified in those in whom baseline fasting glucose exceeds a defined threshold, consistent with reversal of glucotoxicity.
引用
- Retnakaran R, Pu J, Ye C, et al. A Glycemic Threshold Above Which the Improvement of β-Cell Function and Glycemia in Response to Insulin Therapy Is Amplified in Early Type 2 Diabetes: The Reversal of Glucotoxicity. Diabetes Care. 2024. PMID: 39302842. doi:10.2337/dc24-1375
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。